• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Clinical AI Platforms Expand Globally Amid Regulatory and Market Tailwinds

    4/29/25 11:10:00 AM ET
    $ICAD
    $PHG
    $RDNT
    Medical/Dental Instruments
    Health Care
    Medical Electronics
    Health Care
    Get the next $ICAD alert in real time by email

    Equity Insider News Commentary

    Issued on behalf of Avant Technologies Inc.

    VANCOUVER, BC, April 29, 2025 /PRNewswire/ -- Across the western healthcare landscape, artificial intelligence (AI) is being increasingly adopted to simplify authorizations and cut through layers of bureaucratic inefficiency. Rather than replacing physicians — a scenario some tech leaders like Bill Gates have speculated about — the goal is to enhance the capabilities of healthcare professionals. Momentum in this space is being driven by recent initiatives from companies like Avant Technologies, Inc. (OTCQB:AVAI), Koninklijke Philips N.V. (NYSE:PHG), HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF), RadNet, Inc. (NASDAQ:RDNT), and iCad, Inc. (NASDAQ:ICAD).

    Equity Insider Logo (PRNewsfoto/Equity Insider)

    The article continued: Barclays analysts forecast that the AI healthcare market will expand at a robust 30% CAGR through 2030, as investment from hospitals, insurers, and pharmaceutical giants continues to climb. A recent Deloitte study further notes that 71% of healthcare executives expect profitability to rise this year, in large part due to the growing integration of AI technologies into clinical operations.

    Avant Technologies and Ainnova Request Pre-Submission Meeting with US FDA for VisionAI Platform Technology

    Avant Technologies, Inc. (OTCQB:AVAI), an emerging leader in AI-driven healthcare innovation, and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that The Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) has received the company's submission package requesting a pre-submission meeting with the FDA for its VisionAI platform technology and is now under review.

    Ainnova is requesting a pre-submission meeting with the FDA's review team to discuss any questions and/or concerns about its proposed formal submission, including seeking advice to finalize the protocol and obtain agency guidance for a clinical trial of its VisionAI platform in the early detection of diabetic retinopathy. A pre-submission meeting allows companies to clarify regulatory requirements, get feedback on their plans, and potentially avoid delays or issues during the formal review process.

    The clinical studies will aim to support an FDA 510(k) submission to obtain clearance from the regulatory agency to market its technology in the U.S.

    Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, including its VisionAI platform and its versatile retinal cameras, has worldwide licensing rights for this portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States.

    "This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where VisionAI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market," said Vinicio Vargas, CEO at Ainnova and a member of AAC's Board of Directors. "Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product."

    For medical device applicants like Ainnova, the FDA's pre-submission program is useful to determine a clear regulatory pathway for the successful launch of the device, including the number of patients and the number of clinics that will be needed to generate the necessary clinical data for the FDA to make an informed decision on Ainnova's VisionAI platform.

    For Avant, the pre-submission meeting will help define a precise budget for the strategic partnership's entire FDA process.

    This follows Ainnova's recent strategic alignment with Apollo Hospitals in Southeast Asia, where the Vision AI platform has been cleared for commercial deployment in Brazil, and clinical pilots are being prepared across the Americas. Avant and Ainnova have identified Brazil and the United States as key strategic markets. Ainnova is currently addressing regulatory pathways in Brazil with the support of its MDSAP certification to meet ANVISA requirements, paving the way for rapid market entry.

    Ainnova is being guided by global CRO Fortrea ahead of the important pre-submission meeting with the FDA. The goal is to seek 510(k) clearance for Vision AI in detecting diabetic retinopathy, a gateway to broader use across multiple chronic disease categories.

    Between FDA progress, high-profile alliances, and a growing international presence, Avant Technologies continues to carve out a niche in the convergence of AI, diagnostics, and preventative care. Investors looking for small-cap exposure to the healthcare AI revolution may want to keep AVAI on the radar as these developments unfold.

    CONTINUED... Read this and more news for Avant Technologies at:

    https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors- need-to-know/ 

    Philips N.V. (NYSE:PHG) recently announced an expanded partnership with Ibex Medical Analytics to enhance its AI-enabled digital pathology workflows. Their integrated solution helps pathology labs detect cancers more quickly and accurately while boosting productivity by up to 37%.

    "Pathology provides key information for a precise diagnosis," said Sam Terese, President & CEO of Alverno Laboratories. "The Philips and Ibex solutions are especially beneficial to the diagnosis of cancer cases because they aid our pathologists in making an accurate and quick diagnosis. These integrated pathology solutions help us provide the highest possible quality result that any lab can deliver, getting answers back to our clinicians quickly and saving patients sleepless nights, even on complex cases."

    The new PIPS 6.0 system includes cloud archiving, better AI integration, and optimized case management tools. These improvements are designed to ease the growing workload on pathologists and improve patient outcomes worldwide.

    HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF) recently completed its acquisition of Orion Health, significantly expanding its global footprint in healthcare data interoperability and AI-driven solutions. The deal brought access to a large base of public sector clients and 150 million patient records worldwide, strengthening HEALWELL's platform for actionable healthcare insights.

    "The acquisition of Orion Health represents a transformative milestone for the Company, bringing large enterprise customers, recurring revenues, strong operating margins and free cashflow conversion to HEALWELL while providing a significant new channel for the distribution of our best-in-class AI products," said Dr. Alexander Dobranowski, CEO of HEALWELL. "In addition, the acquisition strengthens our position in the public sector, enabling us to deepen our reach with government partners, thanks to Orion Health's strong, long-standing relationships. With the added synergies from WELL Health, we are poised to transform healthcare through AI and data-driven innovation."

    RadNet, Inc. (NASDAQ:RDNT) recently announced plans to acquire iCad, Inc. (NASDAQ:ICAD), aiming to strengthen its leadership in AI-powered breast cancer detection and diagnosis.

    "With over 1,500 healthcare provider locations, facilitating over 8 million annual mammograms in 50 countries, iCAD's installed base and strong sales, engineering and marketing capabilities will provide us with immediate broad and valuable customer relationships and commercialization capabilities that can accelerate our existing DeepHealth objectives," said Dr. Howard Berger, President and CEO of RadNet. "This business combination is expected to accelerate our global leadership and commitment to AI-powered breast cancer screening, and positions us to further advance population health."

    The deal will add iCAD's global network of over 1,500 healthcare locations to RadNet's DeepHealth platform, expanding access to advanced screening technologies. The companies believe the combination will speed up innovation, improve early cancer detection, and enhance patient outcomes worldwide.

    Source: https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors- need-to-know/ 

    CONTACT:

    Equity Insider

    [email protected]

    (604) 265-2873

    DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    Logo: https://mma.prnewswire.com/media/2644233/5292806/Equity_Insider_Logo.jpg

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/clinical-ai-platforms-expand-globally-amid-regulatory-and-market-tailwinds-302441473.html

    SOURCE Equity Insider

    Get the next $ICAD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ICAD
    $PHG
    $RDNT

    CompanyDatePrice TargetRatingAnalyst
    RadNet Inc.
    $RDNT
    6/13/2025$69.00Buy
    B. Riley Securities
    iCAD Inc.
    $ICAD
    4/17/2025Buy → Neutral
    BTIG Research
    iCAD Inc.
    $ICAD
    4/17/2025Buy → Hold
    Laidlaw
    RadNet Inc.
    $RDNT
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    2/25/2025Neutral → Outperform
    Exane BNP Paribas
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    2/20/2025Neutral → Buy
    UBS
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    10/29/2024Underperform → Hold
    Jefferies
    RadNet Inc.
    $RDNT
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $ICAD
    $PHG
    $RDNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on RadNet with a new price target

      B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00

      6/13/25 7:50:00 AM ET
      $RDNT
      Medical Specialities
      Health Care
    • iCAD downgraded by BTIG Research

      BTIG Research downgraded iCAD from Buy to Neutral

      4/17/25 8:29:51 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • iCAD downgraded by Laidlaw

      Laidlaw downgraded iCAD from Buy to Hold

      4/17/25 8:29:51 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    $PHG
    $RDNT
    Leadership Updates

    Live Leadership Updates

    See more
    • New AI Rollouts Signal Shift From Hype to Healthcare Reality

      USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

      6/24/25 9:45:00 AM ET
      $LLY
      $PHG
      $PLTR
      $WAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Electronics
      Computer Software: Prepackaged Software
    • Philips shareholders approve all proposals at the AGM 2025

      May 8, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2025, including: The re-appointment of Ms Indra Nooyi and Ms Chua Sock Koong as members of the Supervisory Board.The appointment of Mr Bob White as a new member of the Supervisory Board.The re-appointment of Mr Marnix van Ginneken as member of the Board of Management. The discharge of the members of the Board of Management, and of the members of the Supervisory Board.A full overview of the resolutions taken at the AGM 2025 can be found below. Feike Sijbesma, Chairman of Philips' Supervisory Board, sa

      5/8/25 12:16:51 PM ET
      $PHG
      Medical Electronics
      Health Care
    • iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer

      NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD. As CCO at iCAD, Koeniguer will assume responsibilities for revenue growth across North America and around the globe, bringing with him extensive executive experience in the medical imaging field and software as a medical device (SaMD) space. In his new role, Mark will have oversight of the commercial sales teams, partnersh

      4/8/25 10:19:01 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    $PHG
    $RDNT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Methodist Hospitals Selects Philips to Advance Neurovascular, Cardiology and Complex Interventional Radiology Services in Northwest Indiana

      Four new interventional labs across Northlake and Southlake campuses enable minimally invasive procedures with improved imaging, reduced radiation and enhanced clinician and patient experience Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, and Methodist Hospitals today announced the healthcare provider's strategic investment in Philips' advanced portfolio of image-guided therapy (IGT) solutions that integrate imaging systems and software, with specialized diagnostic and therapeutic devices. The new interventional suites will support critical health needs within the community including active stroke treatment, oncology therapies, complex cardiovascular interven

      6/25/25 9:06:00 AM ET
      $PHG
      Medical Electronics
      Health Care
    • New AI Rollouts Signal Shift From Hype to Healthcare Reality

      USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

      6/24/25 9:45:00 AM ET
      $LLY
      $PHG
      $PLTR
      $WAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Electronics
      Computer Software: Prepackaged Software
    • AI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals, and Providers

      Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 17, 2025 /PRNewswire/ -- Venture Capital continues to flow in bunches into the AI in healthcare sector, with AI companies capturing more than half of digital health funding in Q1. Investors are seeking novel opportunities that tap into this space, with private companies such as Ellipsis Health and Autonomize AI recently receiving $45M and $28M respectively for their innovations. For other investors seeking opportunities among publicly traded companies, there's been plenty of development to follow from innovators, including from Avant Technologies, Inc. (OTCQB:AVAI), IQVIA Holdings Inc. (NYSE:IQV), S

      6/17/25 10:17:00 AM ET
      $CI
      $IQV
      $RDNT
      $SOUN
      Medical Specialities
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Computer Software: Prepackaged Software

    $ICAD
    $PHG
    $RDNT
    Financials

    Live finance-specific insights

    See more
    • Philips announces exchange ratio for 2024 dividend

      June 5, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that the exchange ratio for the dividend for the year 2024 is 1 new common share for every 23.6353 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 30, June 2, and 3, 2025, of EUR 20.0600 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 22,980,748 new common shares. Shareholders have been given the opportunity to make their choice between a dividend in shares or (subject to certain conditions) in cash. The aggregate cash election

      6/5/25 4:00:00 AM ET
      $PHG
      Medical Electronics
      Health Care
    • RadNet, Inc. Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound Diagnostics

      See-Mode's commercially available AI-powered ultrasound detection, characterization, and reporting solutions for thyroid and breast will be integrated into RadNet's DeepHealth population health solutionsReal-world deployment of See-Mode's FDA-approved thyroid ultrasound solution at RadNet imaging centers demonstrates improved workflow efficiency and enhanced diagnostic accuracy The acquisition positions RadNet at the forefront of AI innovation in ultrasound LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions through its wholly-owned subsidi

      6/4/25 4:01:00 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • iCAD Reports Financial Results for First Quarter Ended March 31, 2025

      NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025.  First Quarter 2025 Highlights (Year over Year Performance): Total ARR (Annual Recurring Revenue) was $10.7 million, up 18% year over yearQ1 total revenues of $4.9 millionGross Profit Margin of 86%92 Total deals closed in Q1, 19 of which were ProFound Cloud Dana Brown, President and CEO of iCAD commented, "We saw meaningful progress this quarter with increasing a

      5/13/25 4:01:00 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    $PHG
    $RDNT
    SEC Filings

    See more

    $ICAD
    $PHG
    $RDNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 425 filed by iCAD Inc.

      425 - ICAD INC (0000749660) (Subject)

      6/30/25 9:30:24 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • SEC Form 425 filed by iCAD Inc.

      425 - ICAD INC (0000749660) (Subject)

      6/16/25 8:19:12 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • RadNet Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - RadNet, Inc. (0000790526) (Filer)

      6/12/25 4:20:27 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • EVP, Chief Science Officer Sorensen Alma Gregory gifted 5,600 shares, decreasing direct ownership by 0.48% to 1,165,345 units (SEC Form 4)

      4 - RadNet, Inc. (0000790526) (Issuer)

      6/18/25 4:15:24 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Director Swartz David L was granted 2,699 shares, increasing direct ownership by 2% to 176,766 units (SEC Form 4)

      4 - RadNet, Inc. (0000790526) (Issuer)

      6/11/25 6:58:58 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Director Spurlock Gregory E. was granted 2,699 shares, increasing direct ownership by 104% to 5,290 units (SEC Form 4)

      4 - RadNet, Inc. (0000790526) (Issuer)

      6/11/25 6:57:48 PM ET
      $RDNT
      Medical Specialities
      Health Care

    $ICAD
    $PHG
    $RDNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by RadNet Inc.

      SC 13G/A - RadNet, Inc. (0000790526) (Subject)

      11/12/24 4:51:53 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RadNet Inc.

      SC 13G/A - RadNet, Inc. (0000790526) (Subject)

      11/4/24 1:22:38 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RadNet Inc.

      SC 13G/A - RadNet, Inc. (0000790526) (Subject)

      10/24/24 6:36:21 PM ET
      $RDNT
      Medical Specialities
      Health Care